Despite having 8 adalimumab biosimilars on the market now, patients may only see 1 or 2 available through their insurance, explained Laura Wingate, executive vice president, Education, Support, & Advocacy, Crohn’s & Colitis Foundation.Having 7 adalimumab biosimilars come to the market at the same time, and a total of 8 launch over the first half […]